Archives

Category Archive for: ‘Competition’

  • Auditing the Goose That Lays Golden Eggs

    Almost everyone is familiar with the Aesop fable of the Goose that Laid the Golden Eggs. In one version: A cottager and his wife had a Hen that laid a golden egg every day. They supposed that the Hen must contain a great lump of …

    Read More
  • The Unaffordable Care Act? Pharmaceutical Drug Coupons Drawing Increased Scrutiny

    A new Bloomberg editorial, “Obamacare Needs to Start Clipping Drug Coupons,” looked at pharmaceutical-sponsored coupons and has concluded “coupons for pricey drugs are a bit of a racket.” The editorial explains: It works like this: Your doctor says you need a drug to, say, treat …

    Read More
  • A Pill Worth 60 Times Its Weight in Gold?

    I read a story the other day about politicians in Washington complaining that a new $1,000 Hepatitis C pill is too expensive. Since these are the guys that helped run up an $18 trillion national debt, I guess you need to take it seriously when …

    Read More
  • Bad Things Happen When Federal Agencies Ignore the Law

    We wrote earlier this year about how the Centers for Medicare and Medicaid Services (CMS) in proposed regulations was essentially ignoring statutory rules to achieve an outcome that CMS bureaucrats thought was preferable to what Congress had written. CMS proposed to misinterpret the straightforward Medicare …

    Read More
  • Everything You Always Wanted to Know About Biosimilars

    In past pieces we have brought to your attention valuable scholarly articles by Emory University Professor Joanna Shepherd on state pharmacy board regulation of PBMs, combatting the prescription painkiller epidemic, the benefits of pharmacy networks, and mandatory disclosure regulations in the prescription drug market. Professor …

    Read More
  • Proposed FDA generic labeling regulation could add $4 billion to annual drug costs

    Prescription labeling rules require drug manufacturers to closely monitor the accuracy of labels on their products once these drugs enter the market and report all findings on drug-related adverse events to the FDA.  Safety information is published in the labeling and can be found in …

    Read More
  • Congress Takes Dim View of Proposed Medicare Part D Rules

    We have written previously about how proposed Medicare Part D regulations would radically revise interpretations of existing rules that keep the government out of negotiations between pharmacies and Medicare prescription drug plans and essentially eliminate cost-saving preferred pharmacy networks. We have also shared with you …

    Read More
  • The changing role of the internet and mobile devices in pharmaceutical marketing

    In recent years, there has been a sea change in pharmaceutical marketing. Unsurprisingly, much of the change is inspired by the rising prominence of information technology, the internet, and the plethora of hand held devices now available. Information that was once accessible only from a …

    Read More
  • Notes from the FTC’s Follow-On Biologics Workshop

    Last year we reported on how biotech companies are lobbying state legislatures to impede cost-saving biosimilars. A New York Times investigation, “Biotech Firms, Billions at Risk, Lobby States to Limit Generics,” revealed how two leading biotech companies, Amgen and Genentech, have been urging state legislatures …

    Read More
  • CMS Tries to Rewrite the Medicare Part D Prime Directive

    Fans of Star Trek know that the United Federation of Planets had a Prime Directive prohibiting Star Fleet crews from interfering in the internal affairs or social development of any of the planets they visited. As Captain Jean-Luc Picard explained, “The Prime Directive is not …

    Read More
Page 1 of 812345»...Last »